We identified six PDX models from the Baylor College of Medicine breast cancer PDX collection according to their PLK2 mRNA expression and known response to carboplatin from an ongoing preclinical trial, and tested the efficacy of volasertib in combination with carboplatin. This evidence concerns the gene PLK2 and breast cancer.